Plasmodium vivax is the most widespread human malaria, putting 2.5 billion people at risk of
infection. Its unique biological and epidemiological characteristics pose challenges to …

Plasmodium vivax and Plasmodium ovale form dormant liver hypnozoites that can reactivate
weeks to months following initial infection. Malaria recurrences caused by relapses are an …

Although global efforts in the past decade have halved the number of deaths due to malaria,
there are still an estimated 219 million cases of malaria a year, causing more than half a …

The technical genesis and practice of 8-aminoquinoline therapy of latent malaria offer
singular scientific, clinical, and public health insights. The 8-aminoquinolines brought …

Introduction: Relapses are important contributors to illness and morbidity in Plasmodium
vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required …

Oxidative agents can cause acute haemolytic anaemia in persons with G6PD deficiency.
Understanding the relationship between G6PD genotype and the phenotypic expression of …

Importance Latent hepaticPlasmodium vivaxhypnozoites provoke repeated clinical attacks
called relapses. Only primaquine phosphate kills hypnozoites, and its therapeutic activity …

Primaquine is the only antimalarial drug available to clinicians for the treatment of relapsing
forms of malaria. Primaquine development and usage dates back to the 1940s and has …

Initiatives to eradicate malaria have a good impact on P. falciparum malaria worldwide. P.
vivax, however, still presents significant difficulties. This is due to its unique biological traits …

The eradication of malaria will only be possible if effective, well-tolerated medicines kill
hypnozoites in vivax and ovale malaria, and thus prevent relapses in patients. Despite …